PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29857559-0	2018	The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia.	RG7388	128-139	transformed mouse 3T3 cell double minute 2	Mus musculus	27-31	
29857559-0	2018	The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia.	RG7388	128-139	transformed mouse 3T3 cell double minute 2	Mus musculus	113-117	
29857559-5	2018	Here we assessed the MDM2 antagonist idasanutlin and the MEK1 inhibitor cobimetinib as single agents and in combination in a variety of AML cell lines and primary AML blast cells for their ability to induce apoptosis and cell death.	RG7388	37-48	transformed mouse 3T3 cell double minute 2	Mus musculus	21-25	
29857559-9	2018	Our data indicate that AML cells with normal karyotype (NK) and wild-type status of TP53 with elevated FLT3 and MDM2 expression emerge to be most sensitive to the combined treatment with cobimetinib and idasanutlin.	RG7388	203-214	transformed mouse 3T3 cell double minute 2	Mus musculus	112-116	
29857559-10	2018	FLT3 and MDM2 are biomarkers for treatment response to idasanutlin and cobimetinib in AML.	RG7388	55-66	transformed mouse 3T3 cell double minute 2	Mus musculus	9-13